Regulus forges new MS pact with Biogen; Pricey new hep C drugs may help all but eliminate the disease;

@FierceBiotech: ICYMI yesterday: Roche's pRED buys out Santaris in $450M RNA acquisition. Article | Follow @FierceBiotech

@JohnCFierce: So, Juno has now raised more than $300M in less than 12 months. Why not go public while they're at it? Release | Follow @JohnCFierce

@DamianFierce: A lot of money: Juno has raised more than $300M in a year to develop a promising new approach to cancer treatment. More | Follow @DamianFierce

> La Jolla, CA-based Regulus Therapeutics has forged a new collaboration agreement with Biogen Idec ($BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis. Regulus gets a $2 million upfront for the deal. Release

> Those pricey new drugs for hepatitis C should help make it a rare disease in the future--but the price will be steep. Story

> Ultragenyx Pharmaceutical struck a license agreement with UniQuest Pty for intellectual property related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with triheptanoin (UX007). Release

Medical Device News

@FierceMedDev: Cohera's surgical adhesive narrowly wins FDA panel support. Article | Follow @FierceMedDev

@StacyALawrence: Smith & Nephew touts acquisitions, offers bulk hospital buying. Story | Follow @StacyALawrence

@VarunSaxena2: ICYMI: FDA announces intention to comprehensively regulate lab-developed tests. Article | Follow @VarunSaxena2

@MichaelGFierce: Nature-inspired artificial cilia could help move drugs to a target. Story | Follow @MichaelGFierce

@EmilyWFierce: Small, portable telemedicine device conducts 33 Dx tests and could improve health monitoring in India. More from Quartz India | Follow @EmilyWFierce

> Nanopores, microfluidics get $14.5M from NIH for new DNA sequencing tech. News

> Earbuds: The wearable med device of the future? Apple, Intel think so. More

> Lombard Medical scores Japanese approval for endovascular stent graft system. Story

> Capnia IPO to raise $20M to market neonatal hemolysis test. Article

Pharma News

@FiercePharma: Best-read news yesterday: Express Scripts hits Amgen, Zogenix as it punts another 25 drugs. Article | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in diabetes franchise. Report | Follow @TracyStaton

@EricPFierce: Impax 0-2 in inspection double header. FDA issues another Form 483 at Hayward, after spanking Taiwan plant. More | Follow @EricPFierce

@CarlyHFierce: GSK private eyes' son allowed first visit to parents in China jail as trial nears. Article | Follow @CarlyHFierce

> Note to Big Pharma: Discounts work. GSK price cuts score Advair a payer boost. Story

> Hep C a rare disease? Drugs from Gilead, J&J, et al. could make it so, but at a price. Item

> Novo Nordisk more valuable than GlaxoSmithKline? That's what investors say. Report

> Is Medicare wasting $220M a year on Questcor's controversial Acthar? More

> Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers. News

Biotech Research News

> Experimental vaccine for C. difficile successful in animal models. Report

> Mice without regulator protein show longer life, fewer tumors. More

> Senate bill would set NIH budget floor, raise funding over 7 years. Article

> Scripps researchers uncover new signaling pathway in brown fat cells. Story

> Peptide measurement predicts Ebola deadliness. Item

Pharma Manufacturing News

> Tough FDA oversight pushing some API makers to look for U.S. expansion. Item

> Novartis' U.S. Diovan plant gets 'For Sale' sign. Article

> FDA piles misery onto Impax with 2nd Form 483 in a week. News

> Labor disputes lead Pfizer to lock workers out of plant in India. Story

> Glenmark to invest $17 million in production facilities in North Carolina. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.